Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Non Small Cell Lung Cancer: early-phase trial registry
16 of 32 indexed Metastatic Non Small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #477 of 28,707 conditions by registered trial count.
32 US clinical trials · 16 currently recruiting · #477 of 28,707 conditions by registered trial count
Metastatic Non Small Cell Lung Cancer: 32 US clinical trials tracked, 16 recruiting.
Metastatic Non Small Cell Lung Cancer is the subject of 32 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is ArriVent BioPharma, running 3 of these trials.
Enrollment posture brief
Registry condition metastatic-non-small-cell-lung-cancer
OPEN 16 | RECR 50% | LATE 11 | EARLY 19 | RANK #477 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Metastatic Non Small Cell Lung Cancer lists 16 open slots (50% of 32 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Non Small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Non Small Cell Lung Cancer is recruiting above its size-band peers.
16 of 32 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Non Small Cell Lung Cancer trials is spread across many organizations.
ArriVent BioPharma accounts for 3 of 32 trials (9.4%). 24 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Non Small Cell Lung Cancer enrolment sits around 250 participants.
Median target enrolment is 250 among the 32 trials that report a genuine target (sentinel values excluded). 11 of those (34.4%) plan for fewer than 100 participants.
-
Metastatic Non Small Cell Lung Cancer research is mostly interventional.
30 interventional and 2 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
32 total, page 1 of 1
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
NCT07222566
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics
NCT04613596
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
NCT06417814
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo
NCT05215340
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NovoCure
NCT06216301
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Memorial Sloan Kettering Cancer Center
NCT04410796
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
ArriVent BioPharma
NCT07185997
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT06343402
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
STORM Therapeutics
NCT06975293
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Iovance Biotherapeutics
NCT04614103
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Obsidian Therapeutics
NCT06060613
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
Virginia Commonwealth University
NCT06731413
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
University of California, Davis
NCT06228482
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Cancer Institute (NCI)
NCT06066138
MOv19-BBz CAR T Cells in FRa+ Cancers
University of Pennsylvania
NCT07116057
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT06863233
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
AstraZeneca
NCT05984277
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Daiichi Sankyo
NCT05555732
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
Eli Lilly and Company
NCT02411448
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
NCT04623775
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Mirati Therapeutics
NCT04685135
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeiGene
NCT05635708
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
ArriVent BioPharma
NCT05607550
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
Merck Sharp & Dohme
NCT05722015
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
ArriVent BioPharma
NCT05364073
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
Bristol-Myers Squibb
NCT07024862
Plasma-Adapted First-Line Pembro In NSCLC
Julia K. Rotow, MD
NCT04166487
Dupilumab_Metastatic NSCLC
Thomas Marron
NCT05013450
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Washington University School of Medicine
NCT04743505
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Incyte Corporation
NCT03679767
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
Novartis Pharmaceuticals
NCT05675683
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT03810807
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 8 |
| Phase 3 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Non Small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Non Small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Non Small Cell Lung Cancer page
32 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 Metastatic Non Small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- ArriVent BioPharma sponsors the most Metastatic Non Small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See ArriVent BioPharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Non Small Cell Lung Cancer condition card totals 32 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.